What is ADC Therapeutics SA (ADCT) stock price today?

ADC Therapeutics SA (ADCT) currently trades at $3.78 per share. The stock has a market capitalization of $480.78M and a P/E ratio of —x.

Is ADCT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, ADC Therapeutics SA has a Smart Value Score of 32/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -6.51.

What is ADC Therapeutics SA's revenue and earnings?

ADC Therapeutics SA has trailing twelve-month (TTM) revenue of $81.36M with profit margins of -175.30%. Earnings per share (EPS) is $-1.12.

Is ADC Therapeutics SA financially healthy?

ADC Therapeutics SA's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -6.51 places it in the distress.

ADCT

ADC Therapeutics SA

NYSE: ADCT · HEALTHCARE · BIOTECHNOLOGY

$3.78

+0.27% today

Updated 2026-04-29

Market cap

$480.78M

P/E ratio

—

P/S ratio

5.91x

EPS (TTM)

$-1.12

Dividend yield

—

52W range

$1 – $5

Volume

0.9M

Market cap

$480.78M

P/E ratio

—

P/S ratio

5.91x

EPS (TTM)

$-1.12

Dividend yield

—

52W range

$1 – $5

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

6.5

Quality

2.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-6.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$8.20

+116.93%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 36.40% QoQ

+ Debt/equity -0.49x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -6.51 — distress zone

- Thin margins at -175.30%

- Negative free cash flow $-31.13M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$209.91M	$69.56M	$70.84M	$81.36M	$81.36M
Net income	$-157.13M	$-240.05M	$-157.85M	$-142.62M	$-6.41M
EPS	—	—	—	—	$-1.12
Free cash flow	$-139.00M	$-121.90M	$-124.70M	$-141.44M	$-31.13M
Profit margin	-74.86%	-345.11%	-222.83%	-175.31%	-175.30%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-13	ZAKI, MOHAMED	Buy	285,200	$3.99
2026-02-13	ZAKI, MOHAMED	Sale	24,603	$3.99
2026-02-13	MALLIK, AMEET	Buy	900,000	$3.99

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ADCT	$480.78M	32	5.3	2.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

ADC Therapeutics SA trades at $3.78. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -6.51, it sits in the distress. TTM revenue stands at $81.36M. with profit margins at -175.30%.

Frequently asked questions

What is ADC Therapeutics SA's stock price?

ADC Therapeutics SA (ADCT) trades at $3.78.

Is ADC Therapeutics SA overvalued?

Smart Value Score 32/100 (Grade F, Strong Sell).

What is the price target of ADC Therapeutics SA (ADCT)?

The analyst target price is $8.20, representing +116.9% upside from the current price of $3.78.

What is ADC Therapeutics SA's revenue?

TTM revenue is $81.36M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-6.51 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE

CurrencyUSD

www.adctherapeutics.com

Quick metrics

P/S ratio5.91x

ROE-706.00%

Beta1.95

50D MA$4.05

200D MA$3.77

Shares out0.13B

Float0.10B

Short ratio—

Avg volume0.9M

Performance

1 week-8.52%

1 month+1.62%

3 months+4.74%

YTD+6.52%

1 year—

3 years—

5 years—

Compare

ADCT vs LLY →ADCT vs JNJ →ADCT vs ABBV →Stock screener →